Responsive Nanocarriers As an Emerging Platform for Cascaded Delivery of Nucleic Acids to Cancer
Overview
Affiliations
Cascades of systemic and intracellular obstacles, including low stability in blood, little tumor accumulation, weak tumor penetration, poor cellular uptake, inefficient endosomal escape and deficient disassembly in the cytoplasm, must be overcome in order to deliver nucleic acid drugs for cancer therapy. Nanocarriers that are sensitive to a variety of physiological stimuli, such as pH, redox status, and cell enzymes, are substantially changing the landscape of nucleic acid drug delivery by helping to overcome cascaded systemic and intracellular barriers. This review discusses nucleic acid-based therapeutics, systemic and intracellular barriers to efficient nucleic acid delivery, and nanocarriers responsive to extracellular and intracellular biological stimuli to overcome individual barriers. In particular, responsive nanocarriers for the cascaded delivery of nucleic acids in vivo are highlighted. Developing novel cascaded nanocarriers that transform their physicochemical properties in response to various stimuli in a timely and spatially controlled manner for nucleic acid drug delivery holds great potential for translating the promise of nucleic acid drugs and achieving clinically successful cancer therapy.
Polymeric nanocarriers for therapeutic gene delivery.
Zhang J, Yang X, Chang Z, Zhu W, Ma Y, He H Asian J Pharm Sci. 2025; 20(1):101015.
PMID: 39931356 PMC: 11808530. DOI: 10.1016/j.ajps.2025.101015.
The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics.
Gunjkar S, Gupta U, Nair R, Paul P, Aalhate M, Mahajan S AAPS PharmSciTech. 2024; 25(8):265.
PMID: 39500822 DOI: 10.1208/s12249-024-02977-6.
Recent advances in nanomaterial-based drug delivery systems for melanoma therapy.
Parhi R, Kaishap P, Jena G ADMET DMPK. 2024; 12(1):107-150.
PMID: 38560710 PMC: 10974823. DOI: 10.5599/admet.2088.
Wang Y, Chen Z, Zhu Q, Chen Z, Fu G, Ma B Bioact Mater. 2024; 37:94-105.
PMID: 38523705 PMC: 10957523. DOI: 10.1016/j.bioactmat.2024.03.019.
Liu X, Zhang Q, Liang Y, Xiong S, Cai Y, Cao J Acta Pharm Sin B. 2023; 13(12):5048-5059.
PMID: 38045048 PMC: 10692376. DOI: 10.1016/j.apsb.2023.07.012.